Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2021-04-30 Annual Report
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
ANNUAL REPORT
Annual Report FY 2020
2021-04-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a press release announcement about a research collaboration, but does not include detailed financial statements or substantive financial data. The document length is 2074 characters, which is relatively short and primarily serves to furnish a press release. According to the rules, such filings that are announcements or furnish press releases without detailed financial data should be classified as Regulatory Filings (RNS).
2021-03-22 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a patent allowance notice from the Japan Patent Office. The document is short (2052 characters) and primarily serves to furnish a press release rather than provide detailed financial data or comprehensive reporting. It does not contain financial statements or substantive financial analysis. Therefore, it is a regulatory filing reporting material corporate news rather than a full report like an annual or interim report.
2021-03-08 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a press release announcement about a new research collaboration. The document length is 2089 characters, which is relatively short and mainly serves to furnish a press release as an exhibit. There are no detailed financial statements or substantive financial data presented. The document is an announcement of information rather than a full report. According to the rules, such filings are best classified as Regulatory Filings (RNS) because they do not fit into other specific categories and are not full reports themselves.
2021-03-01 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 100% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about receiving a patent allowance, but does not contain financial statements or detailed financial data. The document length is short (2041 characters), and it primarily serves as a regulatory announcement rather than a full report. According to the rules, such filings that do not fit other categories and are regulatory announcements fall under Regulatory Filings (RNS).
2021-02-22 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Enlivex Therapeutics Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content describes a press release about the partial exercise of an underwriter's option to purchase additional ordinary shares related to a previously announced underwritten offering. The document is short (2009 characters) and primarily serves as a regulatory filing to disclose this financing update. It does not contain detailed financial statements or comprehensive financial analysis, nor is it an announcement of a report publication. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes.
2021-02-18 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.